Muscle-Specific Promoter Design for Skeletal Muscle Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for muscular dystrophies face challenges in achieving high-level, specific expression of therapeutic proteins in skeletal muscles while minimizing cardiac toxicity, due to the large size of existing promoters and the difficulty in obtaining specificity with smaller promoters.
Innovation Solution
Development of a small-sized synthetic promoter derived from the human ACTA1 gene, comprising a proximal and distal region, which is muscle-specific with higher activity in skeletal muscles and lower activity in the heart, allowing for safe and effective expression of transgenes in neuromuscular diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a large promoter (e.g., human alpha actin ACTA1 promoter) is used to achieve high-level expression in skeletal muscles, then expression level is improved, but promoter size becomes too large for practical applications
Solution Approach 1:
The patent extracts and isolates specific functional elements from the large human alpha actin promoter, including the core promoter region (−153 to +1 relative to the transcription start site) and muscle-specific enhancer elements. By separating and retaining only the essential components necessary for high-level muscle-specific expression, the invention creates a significantly reduced promoter that maintains therapeutic efficacy while fitting within practical vector constraints.
2Length of stationary object
If a small promoter is used to reduce promoter size, then promoter size is improved, but expression specificity in skeletal muscles deteriorates
Solution Approach 1:
The patent applies local quality by concentrating specific muscle-specific enhancer elements at precise locations within the reduced promoter structure. The core promoter (−153 to +1) is combined with strategically positioned enhancer sequences that provide muscle-specific activity. This localized arrangement of functional elements ensures that the small promoter maintains high specificity for skeletal muscle expression while keeping the overall size reduced.
3Productivity
If existing muscle-specific promoters are used to achieve high muscle expression, then expression level in skeletal muscles is improved, but cardiac toxicity increases
Solution Approach 1:
The patent extracts and removes cardiac-active elements from the promoter construction by using a reduced promoter based on the human alpha actin gene that lacks the extensive 5'-flanking regions responsible for cardiac expression. The core promoter (−153 to +1) and selected enhancer elements are sufficient to achieve high muscle expression without the cardiac toxicity associated with full-length promoters, thereby eliminating the harmful effect while preserving the beneficial muscle-specific expression.
Data Source
AI summary
The present invention concerns a novel short promoter characterized by a high activity in the skeletal muscles and a low activity in the heart. It then constitutes a valuable candidate especially for driving the expression of transgenes encoding proteins useful for the treatment of muscular dystrophies.